GlassScriptPhysician profile
Peter R Kinkel
NPI 1831152701
$20,320.03
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,362 · 2021: $2,133 · 2022: $2,055 · 2023: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.05 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $12,233.00 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $2,784.91 | 2019-2023 | Austedo Xr, Austedo, Ajovy |
| Emd Serono, INC. | $819.54 | 2019-2023 | Mavenclad |
| Genzyme Corporation | $717.18 | 2019-2023 | |
| Genentech USA, INC. | $672.36 | 2019-2023 | Ocrevus |
| Biogen, INC. | $466.82 | 2019-2023 | Vumerity, Tysabri |
| Mallinckrodt Hospital Products INC. | $405.94 | 2020-2023 | Acthar |
| Amneal Pharmaceuticals LLC | $376.30 | 2019-2023 | Rytary |
| Abbvie INC. | $268.52 | 2021-2023 | |
| Neurelis, INC. | $229.41 | 2020-2023 | Valtoco |
| Acadia Pharmaceuticals INC | $196.31 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $143.79 | 2019 | |
| Alexion Pharmaceuticals, INC. | $123.82 | 2019-2023 | Ultomiris |
| Amgen INC. | $100.90 | 2019-2022 | |
| Pfizer INC. | $85.25 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $84.84 | 2019-2021 | |
| Axsome Therapeutics, INC. | $80.90 | 2023 | Sunosi |
| Celgene Corporation | $77.37 | 2021-2023 | Zeposia |
| Endo Pharmaceuticals INC. | $56.77 | 2019 | |
| Tg Therapeutics, INC. | $55.64 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.45 | 2022 | |
| Genentech, INC. | $41.02 | 2019-2020 | |
| Neos Therapeutics, LP | $38.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $37.17 | 2020 | |
| Upsher-Smith Laboratories LLC | $34.21 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $32.25 | 2021 | |
| Allergan, INC. | $25.61 | 2020 | |
| Mdd US Operations, LLC | $24.94 | 2020-2022 | |
| Grifols USA, LLC | $24.24 | 2019 | |
| Assertio Therapeutics, INC. | $15.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kinkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.